Skip to main content
OpenTrials
Completed

NCT Number: NCT06867276

Low Level Laser Versus Polarized Light in the Treatment of Acne Vulgaris

The present study is designed to compare clinically the therapeutic applications between low level laser therapy (excimer laser) and non-laser polarized light (Bioptron prol) in the treatment of Acne vulgaris.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Low Level Laser Therapy Acne Vulgaris Acneiform Eruptions Sebaceous Gland Diseases Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

out-patient clinic, faculty of physical therapy, Cairo university

Cairo, Egypt

About this study

Traditional acne treatment often involves topical application, which can cause skin irritation and dryness, and oral antibiotic therapy, which is limited by antibiotic resistance. Newer procedures like laser and light-based therapies offer alternative treatments for patients who struggle with adherence or experience side effects or treatment failure. This study aims to compare the therapeutic application of laser and light therapies as an alternative to traditional acne treatments.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female and male patients.
  • Age range between 18 and 25 years.
  • All patients will sign their informed consent to participate in the research procedure and to publish the data.
  • Definite clinical diagnosis of mild to moderate inflammatory lesions of facial Acne vulgaris (open and closed comedones, papules, pustules, and nodules) on the face that has been going on for at least 1 month.

Exclusion criteria

  • Patient's unwillingness to continue cooperation in the study
  • Photosensitive skin.
  • Pregnancy and breast feeding.
  • Women who use hormonal contraceptives.
  • Patients who had used oral retinoids or any other treatment for acne in the last month.
  • Patients with severe nodulocystic acne

Treatment and study plan

Excimer Laser

Device

Excimer laser patients undergo ultraviolet b phototherapy treatments at a physical medicine clinic twice a week for four weeks. The device uses a 308nm beam of coherent light, with six spot sizes to avoid healthy skin. The radiation exposure time is 10 minutes, with a maximum dose of 0.65 J/cm². Personal protection standards include wearing protective eyewear for the retina and choroid, as they absorb visible light radiation, which can cause keratoconjunctivitis or cataracts. The thermal effect of the laser can cause superficial carbonization of the epidermis, phlyctens, or erythema, so non-flammable gloves are recommended.

Bioptron Pro 1

Device

Patients undergone Bioptron light treatment twice weekly for four weeks at a physical medicine clinic. The treatment is administered by a physiatrist following the manufacturer's user guide. Patients sit in a comfortable chair with their hand on an armrest, holding the Bioptron light probe at a 90° angle for 10 minutes.

Primary outcomes

  1. assessment of change of Global Assessment Scale

    Time frame: At baseline and after 4 weeks

    For the study, we recruited males and females with mild to moderate acne according to the Investigator's Global Assessment (IGA) scale, where the severity of acne and the type of lesions was assigned to it.

    the scoring ranges from 0 to 4. Zero indicates clear skin with no inflammatory and non- inflammatory lesions, while 4 indicates severe lesion with Many comedones and inflammatory lesions, ≤ several nodules and cysts

Secondary outcomes

  1. assesment of change of digital facial photographs

    Time frame: At baseline and after 4 weeks

    Digital Facial photographs, included in the photographic documentation, were taken by (Nikon Camera), before the procedure and four weeks after the end of the whole therapy.

    Digital facial photographs will be taken for each patient at the base line and end of the fourth week to track the development of acne lesions and evaluate treatment effectiveness, using the same method for each patient.

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Mar 10, 2025
Registry last updated
Mar 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.